Russell Angus C. 4

What Happened

• Russell C. Angus, a director of Structure Therapeutics (GPCR), was granted 39,453 derivative ordinary shares in an award reported on Form 4 for transaction date 2026-06-17. The Form 4 shows $0 cash acquisition value for the grant; footnotes indicate the award is derivative (an option-type award) with an exercise price equal to the fair market value per ordinary share based on the issuer's ADS trading price on the grant date.

Key Details

• Transaction date: 2026-06-17; Form 4 filed: 2026-06-18 (timely filing).
• Amount granted: 39,453 ordinary shares (derivative award). Reported acquisition amount: $0.
• ADS equivalence: 1 ADS = 3 ordinary shares, so 39,453 ordinary shares = 13,151 ADS.
• Vesting: Shares vest in equal monthly installments over 12 months beginning June 17, 2026, but will be fully vested no later than the day before the issuer's 2027 annual meeting (per footnote).
• Shares owned after the transaction: not specified in this filing.
• Transaction code: A = Grant/Award (derivative). No sale or immediate disposition reported.

Context

• This filing documents a standard director equity award/option grant used for compensation. The award itself does not indicate a resale or immediate cash realization; exercise would require payment of the exercise price (which is set to FMV per the footnote) and/or future disposition. As with most grants, it’s primarily a compensation event rather than a direct buy/sell signal.